Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gentronix Unveils New Corporate Identity and Website

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Gentronix offers GreenScreen® HC and BlueScreen™ HC assays.

Gentronix has revealed a new corporate identity and re-designed website. The new identity has been developed to reflect how the company has evolved into a mainstream provider of early screening in vitro genetic toxicology assays, and mechanistic follow-up, to a range of business sectors including pharmaceuticals, chemicals, agrochemicals, flavours fragrances and taste enhancers, and the personal care and consumer product industries.

In addition to classical in vitro early screening assays, such as the Ames bacterial mutation reversal and Micronucleus tests, Gentronix offers their proprietary GreenScreen® HC and BlueScreen™ HC assays.

The company also supports clients in the development of de-risking strategies and carrying out further assays to determine the mechanism and causes of positive genotox screening results.

As such, Gentronix has a wealth of knowledge and experience in the field and this is reflected in the new website at www.gentronix.co.uk which hosts content on the science of genotoxicity, regulations for each industry sector, screening procedures, as well as links to an extensive range of peer reviewed papers.

John Nicholson, CEO at Gentronix, comments, “In recent years we have greatly diversified our range of genotoxicity screening product and service offerings. We also provide advice on dealing with positive results and are able to offer a variety of further assays and strategies to help understand the mechanism of genotoxicity. This updating of our corporate identity has been undertaken to better reflect this. These are exciting times for Gentronix, and we feel that the new identity and website helps us to build on our strong foundations to move the business forward.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
Gentronix Ltd. has announced the company's first contracted screening project in Japan, with a major Japanese pharmaceutical manufacturer, Kowa Company, Ltd.
Thursday, October 04, 2012
Gentronix Expands Specialist Sales Team in US and Europe
Expansion of sales teams with the appointments of Dorothy Zelent and Simon Johns.
Friday, February 17, 2012
Gentronix Partner with BioQuanta
The agreement covers the commercialization of the Mitoxis® functional metabolomics platform from BioQuanta.
Thursday, November 10, 2011
Gentronix and Apredica Ally to Create Predictive-Toxicology Service
Joint service offering expected to increase drug development success and the safety of new drugs on the market.
Thursday, June 11, 2009
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Arms Race with a Superbug
Scientists have discovered that increased risk of superbug infection can be directly casued by immune system response to invading bacteria.
Genes Essential to Life Discovered
Genes critical for life are discovered in humans and mice as part of large-scale phenotyping study.
High-Capacity Nanoparticles
New type of nanoparticle can now have three or more drugs packaged within it, allowing for customised cancer therapy.
Manipulation of Liquid Crystals Could Help Control Drug-Delivery Process
Computer modeling, real-world testing yields new method.
Puttng Cells Through Their Paces
An obstacle course for human lung cells could be the answer for better testing the effectiveness of potential new drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!